Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Aug 26

PMID 37631987

Authors

Palaniyandi Muthukutty

So Young Yoo

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses have positively impacted cancer immunotherapy over the past 20 years. Both natural and genetically modified viruses have shown promising results in treating various cancers. Various regulatory authorities worldwide have approved four commercial oncolytic viruses, and more are being developed to overcome this limitation and obtain better anti-tumor responses in clinical trials at various stages. Faster advancements in translating research into the commercialization of cancer immunotherapy and a comprehensive understanding of the modification strategies will widen the current knowledge of future technologies related to the development of oncolytic viruses. In this review, we discuss the strategies of virus engineering and the progress of clinical trials to achieve virotherapeutics.

Citing Articles

Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers.

Filippini D, Broseghini E, Liberale C, Gallerani G, Siepe G, Nobili E J Clin Med. 2025; 14(4).

PMID: 40004705 PMC: 11856027. DOI: 10.3390/jcm14041170.

: A broad platform for the smallest entities shaping the living world.

van der Kuyl A Heliyon. 2025; 10(17):e37228.

PMID: 39958638 PMC: 11829088. DOI: 10.1016/j.heliyon.2024.e37228.

Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS).

Hong Y, Cheng K, Qu H, Wang Y, Wang Y, Fan G J Pharm Health Care Sci. 2024; 10(1):79.

PMID: 39696696 PMC: 11654148. DOI: 10.1186/s40780-024-00388-0.

Newcastle disease virus harboring the PTEN gene inhibits pancreatic cancer growth by inhibiting PI3K/AKT/mTOR signaling and activating apoptosis.

Kim S, Jung B, Kim J, Jeon J, Jang S, Kim M Mol Ther Oncol. 2024; 32(4):200898.

PMID: 39640863 PMC: 11617463. DOI: 10.1016/j.omton.2024.200898.

Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response.

Zhu H, Zhang W, Guo Q, Fan R, Luo G, Liu Y J Immunother Cancer. 2024; 12(11).

PMID: 39615894 PMC: 11624812. DOI: 10.1136/jitc-2024-009901.

References

Lv P, Liu X, Chen X, Liu C, Zhang Y, Chu C . Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy. Nano Lett. 2019; 19(5):2993-3001. DOI: 10.1021/acs.nanolett.9b00145. View

Harrington K, Freeman D, Kelly B, Harper J, Soria J . Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019; 18(9):689-706. DOI: 10.1038/s41573-019-0029-0. View

Muthukutty P, Woo H, Ragothaman M, Yoo S . Recent Advances in Cancer Immunotherapy Delivery Modalities. Pharmaceutics. 2023; 15(2). PMC: 9967630. DOI: 10.3390/pharmaceutics15020504. View

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J . Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022; 28(8):1630-1639. PMC: 9388376. DOI: 10.1038/s41591-022-01897-x. View

Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S . CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 2020; 8(1). PMC: 7057442. DOI: 10.1136/jitc-2019-000131. View

Wang P, Li X, Wang J, Gao D, Li Y, Li H . Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017; 8(1):1395. PMC: 5680234. DOI: 10.1038/s41467-017-01385-8. View

Barton K, Siddiqui F, Pompa R, Freytag S, Khan G, Dobrosotskaya I . Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Mol Ther Oncolytics. 2021; 20:94-104. PMC: 7851493. DOI: 10.1016/j.omto.2020.11.006. View

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

10.

Bishnoi S, Tiwari R, Gupta S, Byrareddy S, Nayak D . Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses. 2018; 10(2). PMC: 5850397. DOI: 10.3390/v10020090. View

11.

Hwang J, Hong J, Yun C . Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. Int J Mol Sci. 2020; 21(22). PMC: 7697902. DOI: 10.3390/ijms21228627. View

12.

Martuza R, Malick A, Markert J, Ruffner K, Coen D . Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252(5007):854-6. DOI: 10.1126/science.1851332. View

13.

Ferguson M, Lemoine N, Wang Y . Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012; 2012:805629. PMC: 3287020. DOI: 10.1155/2012/805629. View

14.

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada J . Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017; 5(1):71. PMC: 5604344. DOI: 10.1186/s40425-017-0277-7. View

15.

Chulpanova D, Solovyeva V, Kitaeva K, Dunham S, Khaiboullina S, Rizvanov A . Recombinant Viruses for Cancer Therapy. Biomedicines. 2018; 6(4). PMC: 6316473. DOI: 10.3390/biomedicines6040094. View

16.

Ganesh S, Edick M, Idamakanti N, Abramova M, VanRoey M, Robinson M . Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007; 67(9):4399-407. DOI: 10.1158/0008-5472.CAN-06-4260. View

17.

Chen N, Szalay A, Buller R, Lauer U . Oncolytic viruses. Adv Virol. 2012; 2012:320206. PMC: 3384932. DOI: 10.1155/2012/320206. View

18.

Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K . Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells. 2021; 10(6). PMC: 8235327. DOI: 10.3390/cells10061541. View

19.

Kim J, Oh J, Park B, Lee D, Kim J, Park H . Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006; 14(3):361-70. DOI: 10.1016/j.ymthe.2006.05.008. View

20.

Guo Z, Lu B, Guo Z, Giehl E, Feist M, Dai E . Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019; 7(1):6. PMC: 6325819. DOI: 10.1186/s40425-018-0495-7. View